Kitos Biotech Kitos Biotech is an italian private company founded in 2016 by two cell and molecular biologists, Francesco P. Fiorentino and Irene Marchesi. The laboratory is located in the scientific park Porto Conte Ricerche, near Alghero (Sardegna, Italia). Kitos biotech offers next-generation, high quality drug discovery services taking advantage of cutting-edge automation systems. - Cutting-edge methodologies - Consultation of experimental design - Tailored assays based on customer needs - Ready-to-publish results - Strict confidentiality - More than 100 cell lines in our stock. - Cell cultures in both monolayer and 3D. - High-throughput screenings. - The best quality at the most competitive price.   **Recent Publications** - Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J. MYCL is a Target of a BET Bromodomain Inhibitor, JQ1, on Growth Suppression Efficacy in Small Cell Lung Cancer Cells. *Oncotarget* 2016 [Epub ahead of print]. - Sanna L, Ortu S, Marchesi I, Bagella P, Fais M, Fiore V, Vidili G, Bagella L, Babudieri S. Evaluation of EZH2 expression in hepatitis B patients. *Infectiuos Diseases and Tropical Medicine*, 2 (4): e349, 2016. - Nieddu V, Pinna G, Marchesi I, Sanna L, Asproni B, Pinna GA, Bagella LM, Murineddu G. Synthesis and antineoplastic evaluation of novel unsymmetrical 1,3,4-oxadiazoles. *Journal of Medicinal Chemistry*, 59 (23), pp 10451–10469, 2016. - Bagella L, Marchesi I. SFK Inhibitors as a New Strategy for RMS Treatment. *Chemotherapy: Open Access*. 5 (2): 1000189, 2016. - Marchesi I, Bagella L. Editorial: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. *World Journal of Clinical Oncology*, 7(2):135-48, 2016. - Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. *Oncotarget* 2016, 7(21):31014-28.